A Study of Two Anti-HIV Drug Combinations in HIV-Infected Patients

In this multicenter, open-label study, 45 HIV-1-positive patients receive either combination drug therapy with delavirdine (DLV), zidovudine (ZDV), and indinavir (IDV) or combination drug therapy with ZDV, lamivudine (3TC), and IDV. NOTE: Patients are treated for 24 weeks and may opt to continue on study for 24 additional weeks, if HIV-1 RNA is less than 5,000 copies/ml or at the investigator's discretion.

Inclusion criteria

Patients must have:

• HIV-1 positive.
• CD4 count above 50.
• HIV-1 RNA greater than 20,000.

Prior Medication:

Allowed:

Less than 1 month prior treatment with zidovudine.

Exclusion criteria

Prior Medication:

Excluded:

• Prior 3TC, protease inhibitors, or non-nucleoside reverse transcriptase inhibitors.
• Prior ZDV of greater than 1 month total duration.

Prior Treatment:

Excluded:

• Lamivudine.
• Protease inhibitors.
• Non-nucleoside reverse transcriptase inhibitors.